Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Short term Debt: 2020-2023

Historic Short term Debt for GeneDx Holdings (WGS) over the last 2 years, with Mar 2023 value amounting to $4.3 million.

  • GeneDx Holdings' Short term Debt rose 33.30% to $4.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $4.3 million, marking a year-over-year increase of 33.30%. This contributed to the annual value of $3.6 million for FY2022, which is 36.98% up from last year.
  • As of Q1 2023, GeneDx Holdings' Short term Debt stood at $4.3 million, which was up 20.09% from $3.6 million recorded in Q4 2022.
  • Over the past 5 years, GeneDx Holdings' Short term Debt peaked at $4.3 million during Q1 2023, and registered a low of $797,000 during Q1 2021.
  • For the 3-year period, GeneDx Holdings' Short term Debt averaged around $2.4 million, with its median value being $2.4 million (2022).
  • Data for GeneDx Holdings' Short term Debt shows a peak YoY skyrocketed of 306.15% (in 2022) over the last 5 years.
  • Over the past 4 years, GeneDx Holdings' Short term Debt (Quarterly) stood at $1.4 million in 2020, then soared by 84.07% to $2.6 million in 2021, then surged by 36.98% to $3.6 million in 2022, then skyrocketed by 33.30% to $4.3 million in 2023.
  • Its Short term Debt stands at $4.3 million for Q1 2023, versus $3.6 million for Q4 2022 and $1.8 million for Q3 2022.